Myokardia Company Profile (NASDAQ:MYOK)

About Myokardia (NASDAQ:MYOK)

Myokardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MYOK
  • CUSIP: N/A
  • Web:
  • Market Cap: $415.21 million
  • Outstanding Shares: 31,455,000
Average Prices:
  • 50 Day Moving Avg: $12.96
  • 200 Day Moving Avg: $13.58
  • 52 Week Range: $10.55 - $22.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $41.27 million
  • Price / Sales: 10.06
  • Book Value: $4.30 per share
  • Price / Book: 3.07
  • EBIDTA: ($15,460,000.00)
  • Net Margins: -248.75%
  • Return on Equity: -43.41%
  • Return on Assets: -35.87%
  • Current Ratio: 6.38%
  • Quick Ratio: 6.38%
  • Average Volume: 124,681 shs.
  • Beta: 6.53
  • Short Ratio: 5.88

Frequently Asked Questions for Myokardia (NASDAQ:MYOK)

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.01. The business had revenue of $5.60 million for the quarter, compared to analyst estimates of $7 million. Myokardia had a negative return on equity of 43.41% and a negative net margin of 248.75%. Myokardia's quarterly revenue was up 55.6% on a year-over-year basis. View Myokardia's Earnings History.

Where is Myokardia's stock going? Where will Myokardia's stock price be in 2017?

5 equities research analysts have issued 1 year price targets for Myokardia's stock. Their forecasts range from $20.00 to $32.00. On average, they expect Myokardia's share price to reach $26.00 in the next twelve months. View Analyst Ratings for Myokardia.

Who are some of Myokardia's key competitors?

Who owns Myokardia stock?

Myokardia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.40%), Wellington Management Group LLP (10.04%), Vanguard Group Inc. (2.18%), Perceptive Advisors LLC (1.99%), Driehaus Capital Management LLC (0.84%) and JPMorgan Chase & Co. (0.75%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Jonathan C Fox, Mark L Perry and Sanofi. View Institutional Ownership Trends for Myokardia.

Who sold Myokardia stock? Who is selling Myokardia stock?

Myokardia's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Driehaus Capital Management LLC, Wells Fargo & Company MN, Morgan Stanley, TIAA CREF Investment Management LLC, Teachers Advisors LLC and United Services Automobile Association. Company insiders that have sold Myokardia stock in the last year include Anastasios Gianakakos and Jake Bauer. View Insider Buying and Selling for Myokardia.

Who bought Myokardia stock? Who is buying Myokardia stock?

Myokardia's stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Point72 Asset Management L.P., TFS Capital LLC, JPMorgan Chase & Co., Vanguard Group Inc. and HarbourVest Partners LLC. Company insiders that have bought Myokardia stock in the last two years include Anastasios Gianakakos, Jonathan C Fox, Mark L Perry and Sanofi. View Insider Buying and Selling for Myokardia.

How do I buy Myokardia stock?

Shares of Myokardia can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Myokardia stock cost?

One share of Myokardia stock can currently be purchased for approximately $13.20.

Analyst Ratings

Consensus Ratings for Myokardia (NASDAQ:MYOK) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.00 (96.97% upside)

Analysts' Ratings History for Myokardia (NASDAQ:MYOK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017BMO Capital MarketsReiterated RatingOutperform$32.00LowView Rating Details
3/13/2017WedbushReiterated RatingOutperform$24.00HighView Rating Details
11/8/2016Cowen and CompanyReiterated RatingBuy$28.00N/AView Rating Details
9/22/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuy$16.00 -> $20.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Myokardia (NASDAQ:MYOK)
Earnings by Quarter for Myokardia (NASDAQ:MYOK)
Earnings History by Quarter for Myokardia (NASDAQ:MYOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myokardia (NASDAQ:MYOK)
2017 EPS Consensus Estimate: ($1.50)
2018 EPS Consensus Estimate: ($1.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.42)($0.42)($0.42)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.40)($0.40)($0.40)
Q3 20181($0.41)($0.41)($0.41)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)


Dividend History for Myokardia (NASDAQ:MYOK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Myokardia (NASDAQ:MYOK)
Insider Ownership Percentage: 46.10%
Institutional Ownership Percentage: 45.43%
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.00View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Myokardia (NASDAQ:MYOK)
Latest Headlines for Myokardia (NASDAQ:MYOK)
DateHeadline logoMyokardia Inc (MYOK) Downgraded by TheStreet to "D+" - May 23 at 5:34 PM logoMyokardia Inc (MYOK) Stock Rating Lowered by Zacks Investment Research - May 14 at 9:12 AM logoMyokardia Inc Expected to Earn Q2 2017 Earnings of ($0.39) Per Share (MYOK) - May 12 at 10:24 AM logoMyokardia Inc (MYOK) Earns "Outperform" Rating from BMO Capital Markets - May 10 at 4:02 PM logoMyoKardia reports 1Q loss - May 10 at 12:12 PM logoMyokardia Inc (MYOK) Announces Earnings Results, Misses Estimates By $0.06 EPS - May 9 at 9:22 PM logoInvestor Network: MyoKardia, Inc. to Host Earnings Call - May 9 at 6:21 PM logoMyoKardia Reports First Quarter 2017 Financial Results and Operational Progress - May 9 at 6:21 PM logoMyokardia (MYOK) Given Coverage Optimism Score of 0.14 - May 8 at 11:44 PM logoMyokardia Inc (MYOK) Receives $25.00 Consensus Price Target from Brokerages - May 6 at 12:50 AM logoMyokardia (MYOK) Receives Daily Coverage Optimism Score of -0.09 - May 3 at 9:49 AM logoMyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 - May 2 at 7:24 PM logoMyokardia Inc (MYOK) Given Average Rating of "Buy" by Brokerages - May 2 at 4:24 PM logoMyokardia (MYOK) Getting Somewhat Positive News Coverage, Report Finds - April 28 at 12:25 AM logoHow a new biotech model looks to disrupt a fatal genetic disease - April 27 at 7:14 PM logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : April 26, 2017 - April 26 at 6:34 PM logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : April 25, 2017 - April 25 at 6:00 PM logoMyokardia (MYOK) Given Daily News Impact Rating of -0.22 - April 23 at 11:02 AM logoShort Interest in Myokardia Inc (MYOK) Drops By 17.7% - April 20 at 5:56 PM logoMyokardia (MYOK) Getting Somewhat Favorable Press Coverage, Report Finds - April 19 at 12:59 PM logoMyoKardia Appoints David Meeker, M.D., to Board of Directors - April 18 at 10:14 AM logoETFs with exposure to MyoKardia, Inc. : April 13, 2017 - April 13 at 6:27 PM logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : April 6, 2017 - April 7 at 11:24 AM logoMyokardia Inc (MYOK) Receives Consensus Recommendation of "Buy" from Analysts - April 5 at 3:40 PM logoInsider Selling: Myokardia Inc (MYOK) Insider Sells 667 Shares of Stock - March 22 at 11:07 PM logoMyokardia Inc (MYOK) CEO Anastasios Gianakakos Sells 1,412 Shares - March 22 at 10:49 PM logoBRIEF-Myokardia appoints Kim Popovits, Wendy Yarno to board - March 18 at 9:09 AM logoMyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors - March 17 at 8:38 AM logoMyokardia Inc (MYOK) to Post Q1 2017 Earnings of ($0.29) Per Share, Wedbush Forecasts - March 15 at 10:11 AM logoBRIEF-Myokardia Q4 net income $14.3 mln - March 13 at 6:26 PM logoMyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress - March 13 at 10:13 AM logoMyoKardia reports 4Q loss - March 13 at 10:13 AM logoMYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 6 at 8:16 AM logo7 Stocks Trending With Monster Volume - March 2 at 9:20 AM logoMyoKardia to Present at Cowen and Company 37th Annual Health Care Conference - February 28 at 10:18 AM logoBRIEF-Myokardia says first subjects dosed in cardiomyopathy drug study - February 3 at 7:28 PM logoFirst Subjects Dosed in Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491 - February 2 at 7:35 PM logoMyoKardia (MYOK) Appoints June Lee as COO - February 2 at 12:47 AM logoMyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs - February 1 at 7:47 PM logoBRIEF-MyoKardia files for mixed shelf offering of up to $250 mln - January 6 at 1:10 AM logoMYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - January 5 at 3:11 AM logoBRIEF-Myokardia says Sanofi has notified company that it has elected to continue global cardiomyopathy research collaboration - January 3 at 10:43 AM logoMyoKardia to Present at 2016 BMO Capital Markets Healthcare Conference - December 8 at 9:50 AM logoBRIEF-Myokardia says got $25 mln payment for deal with Myokardia,Sanofi - December 3 at 11:07 AM logoMyoKardia (MYOK) Receives $25M Milestone Related to MYK-491 Development (SNY) - December 3 at 11:07 AM logoMyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491 - December 2 at 11:12 AM logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : December 1, 2016 - December 1 at 9:24 AM logoMyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer - December 1 at 9:24 AM logo8:05 am MyoKardia appoints Marc Semigran, M.D., as chief medical officer - December 1 at 9:24 AM logoMYOKARDIA INC Financials - November 16 at 6:40 PM



Myokardia (MYOK) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff